![Vaginal ring provides partial protection from HIV in large multinational trial | National Institutes of Health (NIH) Vaginal ring provides partial protection from HIV in large multinational trial | National Institutes of Health (NIH)](https://www.nih.gov/sites/default/files/styles/featured_media_breakpoint-medium/public/news-events/news-releases/2016/20160222-ring.jpg?itok=rHmiE5X6×tamp=1456176919)
Vaginal ring provides partial protection from HIV in large multinational trial | National Institutes of Health (NIH)
![Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial - The Lancet Haematology Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial - The Lancet Haematology](https://www.thelancet.com/cms/attachment/a50f7d53-23d5-44b4-8478-d5afbad96448/gr1_lrg.gif)
Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial - The Lancet Haematology
![NHMRC Clinical Trials Centre Aspirin for the prevention of recurrent venous thromboembolism (VTE) after a first unprovoked event: results of the ASPIRE. - ppt download NHMRC Clinical Trials Centre Aspirin for the prevention of recurrent venous thromboembolism (VTE) after a first unprovoked event: results of the ASPIRE. - ppt download](https://images.slideplayer.com/25/8138004/slides/slide_3.jpg)
NHMRC Clinical Trials Centre Aspirin for the prevention of recurrent venous thromboembolism (VTE) after a first unprovoked event: results of the ASPIRE. - ppt download
![The ASPIRE Trial: TMC435 in treatment-experienced patients with genotype 1 HCV infection who have failed previous PegIFN/RBV treatment: Week 24 interim analysis The ASPIRE Trial: TMC435 in treatment-experienced patients with genotype 1 HCV infection who have failed previous PegIFN/RBV treatment: Week 24 interim analysis](https://www.natap.org/2011/images/040111/methods.gif)
The ASPIRE Trial: TMC435 in treatment-experienced patients with genotype 1 HCV infection who have failed previous PegIFN/RBV treatment: Week 24 interim analysis
![Rationale and design of repeated cross-sectional studies to evaluate the reporting quality of trial protocols: the Adherence to SPIrit REcommendations (ASPIRE) study and associated projects | Trials | Full Text Rationale and design of repeated cross-sectional studies to evaluate the reporting quality of trial protocols: the Adherence to SPIrit REcommendations (ASPIRE) study and associated projects | Trials | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13063-020-04808-y/MediaObjects/13063_2020_4808_Fig1_HTML.png)
Rationale and design of repeated cross-sectional studies to evaluate the reporting quality of trial protocols: the Adherence to SPIrit REcommendations (ASPIRE) study and associated projects | Trials | Full Text
Aspire Fitness - Still searching for that special gift for that special someone? Want to get your loved one into the fitness scene without dropping any hints 😉 Then look no further
![Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma - ScienceDirect Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2152265019320129-gr1.jpg)